Abstract: The present invention relates to a metabolic biomarker set for use in assessing breast cancer in a mammalian subject. In particular, the invention relates to a metabolic biomarker set for screening and/or diagnosing breast cancer, the metabolic biomarker set including at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Further, the invention relates to a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy. Moreover, the present invention relates to a method for assessing breast cancer, which includes obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and/or ratios of metabolites. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess breast cancer.
Type:
Grant
Filed:
March 9, 2021
Date of Patent:
November 8, 2022
Assignee:
Metabolomycs, Inc
Inventors:
Andre Lopes Carvalho, Rene Aloisio Da Costa Vieira, Ismael Dale Cotrim Guerreiro Da Silva, Edson Guimaraes Lo Turco, Therese Koal
Abstract: A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.
Type:
Application
Filed:
October 19, 2021
Publication date:
February 3, 2022
Applicant:
Metabolomycs, Inc.
Inventors:
Robert Nagourney, Ismael Silva, Paulo D'Amora
Abstract: A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.
Type:
Application
Filed:
October 19, 2021
Publication date:
February 3, 2022
Applicant:
Metabolomycs, Inc.
Inventors:
Robert Nagourney, Ismael Silva, Paulo D'Amora
Abstract: A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.
Type:
Grant
Filed:
June 14, 2019
Date of Patent:
November 23, 2021
Assignee:
Metabolomycs, Inc
Inventors:
Robert Nagourney, Ismael Silva, Paulo D'Amora
Abstract: A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.
Type:
Application
Filed:
March 8, 2020
Publication date:
January 7, 2021
Applicant:
Metabolomycs, Inc.
Inventors:
Robert Nagourney, Ismael Silva, Paulo D'Amora
Abstract: A system and method for using new biomarkers to assess individual diseases, including, but not limited to, a patient's prognosis before and/or after being diagnosed with the disease. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and/or treat various diseases, including, but not limited to, COVID-19.
Type:
Application
Filed:
July 6, 2020
Publication date:
December 10, 2020
Applicant:
Metabolomycs, Inc.
Inventors:
Robert Nagourney, Ismael Silva, Paulo D'Amora
Abstract: A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.
Type:
Application
Filed:
December 16, 2019
Publication date:
June 25, 2020
Applicant:
Metabolomycs, Inc.
Inventors:
Robert Nagourney, Ismael Silva, Paulo D'Amora
Abstract: A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.
Type:
Application
Filed:
June 14, 2019
Publication date:
December 19, 2019
Applicant:
Metabolomycs, Inc.
Inventors:
Robert Nagourney, Ismael Silva, Paulo D'Amora